Microbot Medical receives FDA clearance for LIBERTY endovascular robot
Evidence notes
- Microbot Medical received FDA 510(k) clearance for the LIBERTY endovascular robotic system.
- The clearance moved LIBERTY from development into a regulated commercial pathway for endovascular procedures.
- The event anchors Microbot as a surgical robotics pure play with a cleared robotic system.
Company context
Microbot Medical develops LIBERTY, a compact single-use endovascular robotic system designed for remotely operated vascular access and navigation.